Regeneration of our bodies’ own cells is the subject of Biostage ™ - the new corporate name and designation for therapies in treating patients suffering from esophageal, bronchial or tracheal trauma or disease.
Biostage ™ will trade on the NASDAQ as “BSTG” effective April 1.
For years, there’s been a lot of talk about the prospects of cell biology and its impact on regenerative medicine. Billions have and continue to be spent on finding just the right formula to allow the body to heal itself from debilitating and life-threatening disease progressions.
The name, Harvard Apparatus Regenerative Technology (HART) was truly a mouthful of words. Its previous focus needed an upgrade to recognize the newest avenues of cell therapy and their potential in which are now in-place!
The new name sends a clear signal of the transformation of a company from a bioreactor and research tools company to a pioneering biotechnology firm developing bioengineered organ implants for serious and life threatening conditions.